- Home
- BAFN vs MSLE Comparison
BAFN vs MSLE Comparison
Compare BAFN & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BAFN | MSLE |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 186.9M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BAFN | MSLE |
|---|---|---|
| Price | $5.47 | $7.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $25.80 |
| AVG Volume (30 Days) | ★ 127.7K | 56.7K |
| Earning Date | 10-29-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $5.44 |
| 52 Week High | $10.38 | $13.39 |
Technical Indicators
Market Signals| Indicator | BAFN | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 31.26 |
| Support Level | $4.53 | $6.71 |
| Resistance Level | $6.75 | $10.58 |
| Average True Range (ATR) | 0.78 | 0.56 |
| MACD | -0.24 | -0.14 |
| Stochastic Oscillator | 0.00 | 9.62 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.